Strong Revenue Growth:
Full-year 2025 total revenue increased with software up and drug discovery roughly doubling, and early 2026 showed continued expansion in underlying annual contract value with management guiding higher for the year.
Strategic Partnerships:
Multiple new and expanded pharma collaborations and progress in co‑founded companies (e.g., an announced acquisition and positive clinical readouts) provide potential milestone and equity upside that supports growth.
Future-Ready Strategy:
The accelerated shift from on‑premises licenses to hosted, ratable contracts aims to increase predictability, complemented by new offerings such as predictive toxicology and an agentic AI co‑scientist to deepen adoption.
